RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Hepatitis D viremia among injection drug users in San Francisco
Mahale, P., Aka, P. V., Chen, X., Liu, P., Fram, B. J., Wang, A. S., Simenel, S., Tseng, F.-C., Chen, S., Edlin, B. R., Glenn, J. S., & O'Brien, T. R. (2018). Hepatitis D viremia among injection drug users in San Francisco. The Journal of Infectious Diseases, 217(12), 1902-1906. https://doi.org/10.1093/infdis/jiy157
People who inject drugs (PWID) are commonly exposed to hepatitis B virus (HBV) and hepatitis D virus (HDV). We evaluated the prevalence of HDV viremia among hepatitis B surface antigen (HBsAg)-positive PWID (n = 73) using a new quantitative microarray antibody capture (Q-MAC) assay, HDV western blot, and HDV RNA. HDV Q-MAC performed well in this cohort: anti-HDV, 100% sensitivity and specificity; HDV viremia, 61.5% sensitivity and 100% specificity. Hepatitis D viremia was present in 35.6% of HBsAg-positive participants and was more common in those with resolved compared to chronic hepatitis C (5.1% vs 0.6%; adjusted odds ratio, 9.80; P<.0001).